These findings reveal the therapeutic potential targeting of MMP2 in treating CKD and CKD-related cognitive impairment, although further investigations are needed to elucidate the remaining factors resulting in decreased claudin-5 and CD31 expression. Here, CLDN5 is linked to chronic kidney disease.